Key result
Hyperuricaemia was significantly more common in patients with moderate or severe acute cellular rejection than in non-rejecting patients (71% vs 43%, P=0.02; AUC 0.64 for uric acid >7.2 mg/dl).
Why the study?
Does hyperuricaemia predict acute cellular rejection in patients after first heart transplantation?
Cohort (n=114)
Does hyperuricaemia predict acute cellular rejection in patients after first heart transplantation?
Effect estimate: AUC 0.64
p-value: p=0.02
Hyperuricaemia (uric acid >7.2 mg/dl) may serve as a useful non-invasive prognostic marker for identifying patients at high risk of acute cellular rejection during the first year after heart transplantation.
No takes yet. Share an insight, caveat, or question.
Hyperuricaemia may aid non-invasive rejection risk assessment after heart transplant; leaves open whether monitoring should guide surveillance or therapy.
António et al. (2010) conducted a cohort in Heart transplantation (n=114). Hyperuricaemia (uric acid > 7.2 mg/dl) vs. Uric acid ≤ 7.2 mg/dl was evaluated on Moderate or severe acute cellular rejection (ISHLT grade ≥2R) (AUC 0.64, p=0.02). Hyperuricaemia was significantly more common in patients with moderate or severe acute cellular rejection than in non-rejecting patients (71% vs 43%, P=0.02; AUC 0.64 for uric acid >7.2 mg/dl).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: